ASMANEX HFA

Peak

mometasone furoate

NDAINHALATIONAEROSOL, METERED
Approved
Apr 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
17

Mechanism of Action

anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of inhibitory effects on multiple cell types (e.g., mast cells, eosinophils,…

Indications (1)

Clinical Trials (5)

NCT05776927Phase 3Not Yet Recruiting

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

Started May 2026
304 enrolled
Asthma
NCT05562466Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

Started May 2023
200 enrolled
Asthma
NCT04589663Phase 2Completed

Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to < 12 Years Old With Asthma

Started Jun 2021
24 enrolled
Asthma
NCT02554786Phase 3Completed

A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma

Started Dec 2015
2,216 enrolled
Asthma
NCT02397915Phase 4Completed

Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays

Started Mar 2015
300 enrolled
Rhinitis, Allergic, Perennial and Seasonal